Group	Essential
Name	Contao HTTPS CSRF Token
Technical name	csrf_https-contao_csrf_token
Provider
Expire in days	0
Privacy policy
Use	Used to protect the encrypted website (HTTPS) from forgery of cross-site requests. After closing the browser the cookie is deleted again
Allowed
Name	PHP SESSION ID
Technical name	PHPSESSID
Provider
Expire in days	0
Privacy policy
Use	Cookie from PHP (programming language), PHP data identifier. Contains only a reference to the current session. No information is stored in the user's browser and this cookie can only be used by the current website. This cookie is mainly used in forms to increase the user experience. Data entered in forms is stored for a short time, for example, if there is an input error by the user and the user receives an error message. Otherwise, all data would have to be entered again. Translated with www.DeepL.com/Translator (free version)
Allowed
Group	Analysis
Name	Matomo
Technical name	_pk_ses.2.7a1c,_pk_id.2.7a1c
Provider	Matomo
Expire in days	72
Privacy policy
Use	Matomo Tracking
Allowed

Publication

Economic evaluation of maintenance treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis

Wollenberg A, Sidhu MK, Odeyemi I, Dorsch B, Koehne-Volland R, Schaff M, Ehlken B, Berger K.

Br J Dermatol. 2008 Dec;159(6):1322-30. doi: 10.1111/j.1365-2133.2008.08807.x. Epub 2008 Sep 6.
PMID: 18782316

Abstract

Background:

Rational health care decision-making based on outcomes and economic evidence is essential to provide the best possible care for individual patients with atopic dermatitis (AD).

Objectives:

To describe treatment outcomes and to evaluate resource utilization and associated cost of maintenance use of tacrolimus ointment (MU) vs. standard use of tacrolimus ointment (SU) in adults with AD.

Methods:

A pan-European, phase III multicentre randomized clinical trial was conducted. Patients with mild to severe AD were randomized to tacrolimus 0.1% ointment (MU) or vehicle (SU) twice per week for 12 months. Disease exacerbations were treated by using open-label tacrolimus 0.1% ointment twice daily. Resource utilization data were collected prospectively alongside the clinical trial. Costs of pooled resource data were determined using German unit cost data. Direct and indirect costs were considered from third party payer, patient and societal perspectives.

Results:

All patients with moderate and severe AD were included in a subanalysis, 75 patients in the MU arm (57% moderately affected) and 59 patients in the SU arm (59% moderately affected). In patients with moderate AD, the number of disease exacerbations in the MU arm was 2.4 vs. 5.5 in the SU arm (P<0.001); in patients with severe AD corresponding figures were 2.3 vs. 7.4 (P<0.001), respectively. Mean+/-SD total annual cost per patient was euro1525+/-1081 (MU) vs. euro1729+/-1209 (SU) in patients with moderate AD and euro2045+/-2013 (MU) vs. euro2904+/-1510 (SU) in patients with severe AD.

Conclusion:

Maintenance treatment with 0.1% tacrolimus ointment is more effective and leads to cost savings and improved health-related quality of life in comparison with standard use of 0.1% tacrolimus ointment, especially in patients with severe AD.

Whitepaper and Publications overview